[go: up one dir, main page]

MX2010003511A - Método optimizado y definido para el aislamiento y conservación de células precursoras del cordón umbilical humano. - Google Patents

Método optimizado y definido para el aislamiento y conservación de células precursoras del cordón umbilical humano.

Info

Publication number
MX2010003511A
MX2010003511A MX2010003511A MX2010003511A MX2010003511A MX 2010003511 A MX2010003511 A MX 2010003511A MX 2010003511 A MX2010003511 A MX 2010003511A MX 2010003511 A MX2010003511 A MX 2010003511A MX 2010003511 A MX2010003511 A MX 2010003511A
Authority
MX
Mexico
Prior art keywords
cells
umbilical cord
optimized
isolation
precursor cells
Prior art date
Application number
MX2010003511A
Other languages
English (en)
Inventor
Rita Isabel Ganchas Soares
Maria Constanca Baptista Coelho
Jorge Miguel Silva Santos
Pedro Estilita Da Cruz
Jose Paulo Martins
Vera Alexandra Basto
Helder Joaquim Soares Da Cruz
Original Assignee
Medinfar Produtos Farmaceutico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinfar Produtos Farmaceutico filed Critical Medinfar Produtos Farmaceutico
Publication of MX2010003511A publication Critical patent/MX2010003511A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0604Whole embryos; Culture medium therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0668Mesenchymal stem cells from other natural sources
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un método optimizado y definido para el aislamiento y conservación de células precursoras a partir del cordón umbilical humano. Además de ser reproducible y 100% confiable en términos del número de muestras procesadas, el método resulta en un número alto y definido de células precursoras, la mayoría que se obtienen después de una fase de adhesión sencilla y de expansión/multiplicación ex vivo (otorgando así un fenotipo celular), en un marco de tiempo más corto que aquel que fue previamente descrito en el estado del arte. Con este método, es posible obtener en 9 días, después de congelamiento directo de una fracción celular, y después de una fase de expansión/multiplicación ex vivo (final de PO) de la mayoría de las células, alrededor de 8.6 (±0.1) x 105 células/gramo de cordón umbilical procesado. A su vez, las características de las células permiten por ejemplo, después de 35 días, obtener un promedio de 7.7 x 1015 células, con fenotipo del precursor, a partir del 100% de las muestras procesadas de cordón umbilical. El método, debido a que es sencillo, sólido y 100% confiable, se puede efectuar bajo buenas prácticas de manufactura (GMP) en laboratorios dedicados a la terapia celular en humanos. Además, el método tiene aplicaciones las áreas farmacéutica, de cosmética y biotecnología.
MX2010003511A 2007-10-04 2008-10-03 Método optimizado y definido para el aislamiento y conservación de células precursoras del cordón umbilical humano. MX2010003511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT103843A PT103843B (pt) 2007-10-04 2007-10-04 Método de isolamento de células precursoras a partir do cordão umbilical humano
PCT/IB2008/054067 WO2009044379A2 (en) 2007-10-04 2008-10-03 Optimised and defined method for isolation and preservation of precursor cells from human umbilical cord

Publications (1)

Publication Number Publication Date
MX2010003511A true MX2010003511A (es) 2010-09-10

Family

ID=40456372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003511A MX2010003511A (es) 2007-10-04 2008-10-03 Método optimizado y definido para el aislamiento y conservación de células precursoras del cordón umbilical humano.

Country Status (15)

Country Link
US (1) US9546353B2 (es)
EP (1) EP2203555B1 (es)
JP (1) JP5785394B2 (es)
KR (1) KR20100087705A (es)
CN (1) CN101868536B (es)
AU (1) AU2008306442B2 (es)
BR (1) BRPI0817522A2 (es)
CA (1) CA2701907A1 (es)
EA (1) EA025532B1 (es)
ES (1) ES2582369T3 (es)
IL (1) IL204788A (es)
MX (1) MX2010003511A (es)
PT (1) PT103843B (es)
WO (1) WO2009044379A2 (es)
ZA (1) ZA201002260B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2576768T3 (en) 2010-06-01 2017-08-28 Auxocell Laboratories Inc NATIVE WHARTONS JELLY STEM CELLS AND CLEANING THEREOF
CN104204190B (zh) * 2010-10-18 2017-02-01 尚翔股份有限公司 人类多能性类胚胎干细胞先驱细胞
TWI535377B (zh) * 2011-09-01 2016-06-01 Storage, culture and application of umbilical cord tissue and its derived cells
WO2013102219A1 (en) 2011-12-30 2013-07-04 Amit Patel Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses
CN102550543B (zh) * 2012-02-10 2014-04-16 四川新生命干细胞科技股份有限公司 用于保存脐带组织的液体
CN103461322B (zh) * 2012-06-07 2016-08-03 西比曼生物科技(上海)有限公司 用于冻存复苏后的细胞的保存液
EP2756754B1 (de) 2013-01-17 2017-01-04 Vita 34 Ag Verfahren zur Behandlung von Nabelschnurgewebe, insbesondere im Zusammenhang mit der Konservierung des Gewebes
US20170119824A1 (en) * 2014-05-24 2017-05-04 Neelam Krishnan Venkataramanaa A method for the treatment of glioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord
CA2964163A1 (en) * 2014-11-05 2016-05-12 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
US10006003B2 (en) * 2015-06-30 2018-06-26 Surgenex, LLC Compositions and methods for flowable allograft amniotic tissue
WO2017096611A1 (zh) * 2015-12-11 2017-06-15 郭镭 一种从脐带华通氏胶组织中分离培养脐带间充质干细胞的方法
WO2019175773A1 (en) 2018-03-12 2019-09-19 Universidade Do Porto Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells
CN112342191A (zh) * 2019-08-07 2021-02-09 路春光 hMSC生产试剂盒开发和质量管理标准优化和体系建立
CN111893092A (zh) * 2020-06-28 2020-11-06 国大生命科学产业集团(深圳)有限公司 一种人脐带来源的间充质干细胞及其制备方法
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
DE102021116694B4 (de) * 2021-06-29 2023-03-09 Promocell Gmbh Wässrige Lösung zur Zellkonservierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402890B (de) * 1994-03-16 1997-09-25 Berbi Gmbh Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln
AU2003221173A1 (en) * 2002-03-27 2003-10-08 Asahi Kasei Kabushiki Kaisha Placenta-origin mesenchymal cells and medicinal use thereof
JP2009521931A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法
PL2089511T3 (pl) * 2006-11-13 2015-02-27 Depuy Synthes Products Llc Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki

Also Published As

Publication number Publication date
PT103843B (pt) 2008-08-12
CN101868536B (zh) 2015-03-25
IL204788A0 (en) 2010-12-30
EP2203555B1 (en) 2016-04-13
CA2701907A1 (en) 2009-04-09
EP2203555A2 (en) 2010-07-07
KR20100087705A (ko) 2010-08-05
US9546353B2 (en) 2017-01-17
JP2010539970A (ja) 2010-12-24
WO2009044379A3 (en) 2009-05-22
US20100216237A1 (en) 2010-08-26
EA201000425A1 (ru) 2010-10-29
ZA201002260B (en) 2011-06-29
ES2582369T3 (es) 2016-09-12
IL204788A (en) 2013-07-31
AU2008306442A1 (en) 2009-04-09
BRPI0817522A2 (pt) 2014-10-14
JP5785394B2 (ja) 2015-09-30
WO2009044379A2 (en) 2009-04-09
PT103843A (pt) 2008-01-09
EA025532B1 (ru) 2017-01-30
AU2008306442B2 (en) 2014-12-04
CN101868536A (zh) 2010-10-20

Similar Documents

Publication Publication Date Title
MX2010003511A (es) Método optimizado y definido para el aislamiento y conservación de células precursoras del cordón umbilical humano.
Neri et al. Molecular mechanisms contributing to mesenchymal stromal cell aging
Dinescu et al. Biocompatibility Assessment of Novel Collagen‐Sericin Scaffolds Improved with Hyaluronic Acid and Chondroitin Sulfate for Cartilage Regeneration
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
Yoon et al. Thermosensitive, stretchable, and piezoelectric substrate for generation of myogenic cell sheet fragments from human mesenchymal stem cells for skeletal muscle regeneration
Jian et al. Bioinspired self‐growing hydrogels by harnessing interfacial polymerization
WO2008073635A3 (en) Automatable artificial immune system (ais)
EP3190180A3 (en) A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2007108835A3 (en) Automatable artificial immune system (ais)
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
HK1203219A1 (en) Method of treatment employing therapeutic t cell product from mobilised donors
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
BRPI0619579B8 (pt) Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
NZ630598A (en) Method of engrafting cells from solid tissues
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
MX2016005824A (es) Metodo de cultivo celular.
EP4338803A3 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
NZ593365A (en) Pharmaceutical preparation comprising a blood mononuclear cell culture
AR053827A1 (es) Composiciones de tigeciclina y metodos de preparacion
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CL2007003357A1 (es) Anticuerpo o fragmento funcional del mismo capaz de inhibir la proliferacion de celulas tumorales in vitro y/o in vivo; acido nucleico que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar el cancer.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration